Surgeon bias in sentinel lymph node dissection: Do tumor characteristics influence decision making?

Breast. 2014 Dec;23(6):790-2. doi: 10.1016/j.breast.2014.08.007. Epub 2014 Aug 28.

Abstract

Background: Determining sentinel lymph nodes (SLNs) in breast cancer staging involves subjective interpretation by the surgeon. We hypothesized patient and tumor characteristics influence number of SLNs harvested.

Methods: A single-institution, prospectively collected database was queried for breast cancer patients undergoing SLN surgery (2002-2013) and mean SLN counts were compared.

Results: There were 2394 SLN biopsies. Mean number of SLNs per patient for the entire cohort was 2.6. Mean number of SLNs removed was greater for patients ≤50 years (2.9 versus 2.6; p < 0.0001). Fewer SLNs were removed with tumors ≤1 cm (2.5 versus 2.6; p = 0.002). Patients with grades 2 or 3 tumors had more SLNs removed than grade 1 (2.6 versus 2.5; p = 0.03). Receipt of neoadjuvant therapy was associated with more SLNs removed (3.0 versus 2.6; p = 0.005).

Conclusion: Number of SLNs removed varies based on risk factors for SLN metastasis or false-negative SLN biopsy.

Keywords: Breast cancer staging; Sentinel lymph node biopsy; Surgeon bias.

MeSH terms

  • Age Factors
  • Aged
  • Axilla
  • Bias
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery*
  • Carcinoma, Ductal, Breast / pathology
  • Carcinoma, Ductal, Breast / surgery*
  • Carcinoma, Intraductal, Noninfiltrating / pathology
  • Carcinoma, Intraductal, Noninfiltrating / surgery*
  • Carcinoma, Lobular / pathology
  • Carcinoma, Lobular / surgery*
  • Databases, Factual
  • Decision Making
  • Female
  • Humans
  • Lymph Node Excision / methods
  • Lymph Node Excision / statistics & numerical data
  • Lymph Nodes / pathology*
  • Male
  • Middle Aged
  • Neoadjuvant Therapy / statistics & numerical data*
  • Neoplasm Grading
  • Neoplasm Staging
  • Prospective Studies
  • Sentinel Lymph Node Biopsy / methods
  • Sentinel Lymph Node Biopsy / statistics & numerical data*
  • Tumor Burden